Andrew Bryant
Jan Lecouturier
Giovany Orozco Leal
Dr Vicky Brocklebank
Dr Sonya Carnell
et al. | Clinical and cost-effectiveness of eculizumab withdrawal in atypical haemolytic uraemic syndrome: the SETS aHUS multi-centre, open-label, prospective and single-arm study | 2026 |
|
Professor David Kavanagh
| Current and Emerging Therapies for C3 Glomerulopathy and Primary (Idiopathic) Immune Complex Membranoproliferative Glomerulonephritis | 2026 |
|
Professor David Kavanagh
| Pegcetacoplan for adults with C3G or primary IC-MPGN who had a kidney transplant: plain language summary of the NOBLE trial | 2026 |
|
Giovany Orozco Leal
Professor Luke Vale
Dr Vicky Brocklebank
Andrew Bryant
Dr Thomas Chadwick
et al. | The cost-effectiveness of replacing lifelong therapy of eculizumab with a strategy of disease monitoring for eligible atypical haemolytic uraemic syndrome (aHUS) patients: an economic evaluation of the SETS aHUS trial | 2026 |
|
Dr Patrick Walsh
Professor David Kavanagh
| Atypical Haemolytic Uraemic Syndrome | 2025 |
|
Andrew Bryant
Jan Lecouturier
Giovany Orozco Leal
Dr Vicky Brocklebank
Dr Sonya Carnell
et al. | Eculizumab withdrawal and monitoring in atypical haemolytic uraemic syndrome (SETS aHUS): a multicentre, open label, prospective, single arm trial | 2025 |
|
Professor David Kavanagh
| Efficacy and Safety of Pegcetacoplan in Kidney Transplant Recipients With Recurrent Complement 3 Glomerulopathy or Primary Immune Complex Membranoproliferative Glomerulonephritis | 2025 |
|
Professor David Kavanagh
| Factor B as a therapeutic target for the treatment of complement-mediated diseases | 2025 |
|
Professor David Kavanagh
| Kidney Complement Immunohistochemistry in Thrombotic Microangiopathy Subtypes | 2025 |
|
Emily Glover
Professor David Kavanagh
Professor Neil Sheerin
| Kidney Transplantation in Patients with aHUS: A Comparison of Eculizumab Prophylaxis Versus Rescue Therapy | 2025 |
|
Emily Glover
Dr Emma Montgomery
Dr Edwin Wong
Dr Michal Malina
Professor Kevin Marchbank
et al. | Late Onset Thrombotic Microangiopathy in Kidney Transplants; Poor Outcome Despite Eculizumab Treatment | 2025 |
|
Dr Katrina Wood
Professor David Kavanagh
| Misdirected yet intact TREX1 exonuclease activity causes human cerebral and systemic small vessel disease. | 2025 |
|
Professor David Kavanagh
Dr Edwin Wong
| Oral iptacopan therapy in patients with C3 glomerulopathy: a randomised, double-blind, parallel group, multicentre, placebo-controlled, phase 3 study | 2025 |
|
Professor David Kavanagh
| Post-transplant Thrombotic Microangiopathy | 2025 |
|
Laura Bailey
Vikki Bridgett
Dr Vicky Brocklebank
Dr Sally Johnson
Professor David Kavanagh
et al. | Quantifying association of early proteinuria and estimated glomerular filtration rate changes with long-term kidney failure in C3 glomerulopathy and immune-complex membranoproliferative glomerulonephritis using the United Kingdom RaDaR Registry | 2025 |
|
